文献速递腹部介入CTPET

通过代谢成像、切缘评估与活检优化结直肠癌肝转移消融(OPTABLATE前瞻性试验)

Optimizing Colorectal Liver Metastasis Ablation through Metabolic Imaging, Margin Assessment, and Biopsy (The OPTABLATE Prospective Trial).
PubMed 文献 · Radiology · 2026-01-01

这项前瞻性单中心试验纳入77例接受PET/CT引导微波消融的结直肠癌肝转移患者(共104个病灶),术中联合最小消融切缘、快速组织活性评估和PET代谢信息判断是否需要即刻再消融。14%的病灶按标准接受了即刻再消融,最小消融切缘大于5 mm与局部肿瘤进展风险降低相关(亚分布风险比0.12,95%CI 0.05–0.30,P<.001)。

要点

  • 最小消融切缘大于5 mm者局部肿瘤进展风险显著降低,亚分布风险比0.12(95%CI 0.05–0.30,P<.001)。
  • 104个病灶中15个(14%)按切缘小于5 mm、残留PET摄取或快速组织评估阳性接受即刻再消融。
  • 最小消融切缘大于10 mm的病灶未观察到局部肿瘤进展。

核心结论

  • 最小消融切缘仍是影响肿瘤控制的关键技术因素,所提出的多模态消融区综合评估使14%初始消融不充分的病灶得以即刻再消融并改善局部肿瘤控制。

研究设计与样本

  • 前瞻性单中心试验,2019年11月至2023年2月纳入77例接受PET/CT引导微波消融的结直肠癌肝转移患者(104个病灶),中位年龄56岁(IQR 47–64.5岁),39例男性;以快速组织评估(印迹细胞学与荧光活性染色)及PET/CT和增强CT为参考判断残留存活肿瘤。

关键影像表现/征象

  • 消融区中心及切缘取材行快速组织评估检测存活肿瘤细胞,12个初始存活肿瘤细胞阳性消融区再消融后重复活检均为阴性。
  • 7个切缘小于5 mm的消融区中5个在再消融后切缘增至大于5 mm。
  • 因PET/CT表现接受再消融的4个病灶消融区均存活肿瘤细胞阳性,其中1个切缘小于5 mm。

诊断标准与关键数值

  • 即刻再消融标准为增强CT示最小消融切缘小于5 mm、残留PET高代谢肿瘤和/或快速组织评估检出存活肿瘤细胞中任一项。
  • 最小消融切缘大于5 mm对局部肿瘤进展有保护作用,亚分布风险比0.12(95%CI 0.05–0.30,P<.001)。
  • 活检证实完全消融且最小消融切缘大于5 mm者1年、2年、3年累积局部肿瘤进展发生率分别为7%、12%、12%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Real-time methods are needed for intraprocedural detection of residual tumors and incomplete thermal ablation (TA) to allow immediate retreatment and tumor eradication. Purpose To validate a TA workflow for detecting and immediately ablating residual viable colorectal liver metastases (CLMs). Materials and Methods This prospective single-center trial enrolled participants who underwent PET/CT-guided microwave CLM ablation from November 2019 to February 2023. The minimal ablation margin (MM) was calculated in all directions. Biopsies were obtained from the ablation zone (AZ) center and margin, with rapid tissue assessment for viable tumor (VT) cells using imprint cytology and fluorescent viability staining. Immediate reablation was performed if any of the following criteria were met: MM less than 5 mm at contrast-enhanced CT, residual PET-avid tumor, and/or VT cells at rapid tissue assessment. Gray-model statistics quantified the MM and VT impact on local tumor progression subdistribution hazard amid the competing risk of death. Results Seventy-seven participants (median age, 56 years [IQR, 47-64.5 years]; 39 male participants) underwent ablation in 104 CLMs. Overall, 15 of 104 (14%) CLMs underwent immediate reablation per the criteria (12 of 15, VT; seven of 15, MM <5 mm; and four of 15, residual fluorodeoxyglucose avidity). After reablation, all 12 initially VT-positive AZs underwent repeat biopsies with negative findings. Five of seven MMs less than 5 mm in AZs increased to greater than 5 mm after reablation. All four CLMs that underwent reablation due to PET/CT findings had AZs positive for VT, and one had MM less than 5 mm. MM greater than 5 mm protected against local tumor progression (LTP) (subdistribution hazard ratio, 0.12; 95% CI: 0.05, 0.30; P < .001). There was no LTP for MMs greater than 10 mm. The cumulative LTP incidence at 1, 2, and 3 years for participants with biopsy-proven completely ablated CLMs with MM greater than 5 mm was 7%, 12%, and 12%, respectively. Conclusion MM remained a critical technical factor affecting tumor control; the proposed multimodal comprehensive AZ assessment enabled immediate onsite reablation of 14% of CLMs with initially insufficient ablation treatment and improved local tumor control after thermal ablation. ClinicalTrials.gov identifier: NCT04143516 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Georgiades in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Dimopoulos MP, Sotirchos VS, Vakiani E, et al. Optimizing Colorectal Liver Metastasis Ablation through Metabolic Imaging, Margin Assessment, and Biopsy (The OPTABLATE Prospective Trial). Radiology. 2026. PMID: 41874299. doi:10.1148/radiol.250864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。